Allergen immunotherapy: clinical outcomes assessment

Area of Science:

• Allergy and Immunology
• Clinical Trials
• Evidence-Based Medicine

Background:

• Clinical outcome assessment is crucial for evaluating allergen immunotherapy (AIT) efficacy in trials and practice.
• Primary outcomes in AIT trials commonly include symptom measurement and medication use.
• Secondary outcomes encompass symptom scores, allergen tests, visual analog scales, and quality of life.

Purpose of the Study:

• To review primary and secondary outcome parameters used in AIT clinical trials.
• To examine recommendations from European and US guidelines and allergy groups.
• To explore applicable outcome measures for clinical practice.

Main Methods:

• Systematic review of published AIT clinical trials.
• Analysis of outcome parameters reported in trial methodologies.
• Comparison of trial outcomes with existing clinical guidelines and expert recommendations.

Main Results:

• Significant inconsistency exists in the selection of outcome parameters across AIT trials.
• Lack of standardized outcome measures hinders direct comparison of therapeutic interventions.
• Guidelines offer recommendations, but their adoption in practice varies.

Conclusions:

• Standardization of outcome measures in AIT is essential for reliable efficacy assessment.
• A consensus on primary and secondary outcomes would improve trial comparability and clinical decision-making.
• Further research and guideline implementation are needed to harmonize outcome assessment in AIT.